Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced new preclinical data from its immuno-oncology portfolio, including TNX-1700 and TNX-4700, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego. The data were featured in one oral and two poster sessions, highlighting the company's progress in developing novel cancer therapies.
TNX-1700, a potential treatment for gastric cancer, demonstrated the ability to reduce inflammation and tumor progression in preclinical models. The compound also showed favorable pharmacokinetics, supporting its further development. Gastric cancer remains a significant unmet medical need, with limited treatment options, making TNX-1700 a promising candidate for patients.
TNX-4700, a monoclonal antibody targeting BTLA (B- and T-lymphocyte attenuator), displayed promising in vitro activity. BTLA is an immune checkpoint receptor that suppresses T-cell activation, and its inhibition could enhance anti-tumor immune responses. The data suggest TNX-4700 may be effective as a monotherapy or in combination with other checkpoint inhibitors, such as PD-1 or CTLA-4 blockers, potentially broadening its therapeutic utility.
Tonix Pharmaceuticals is a fully integrated commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments. The company's recently approved medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in over 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including Zembrace SymTouch and Tosymra for acute migraine. The company is also exploring TONMYA's potential in Phase 2 trials for major depressive disorder and acute stress disorder.
Beyond oncology, Tonix's immunology pipeline includes TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection. The company's CNS pipeline features TNX-2900, which is Phase 2 ready for Prader-Willi syndrome.
The presentation of these data at AACR 2026 underscores Tonix's commitment to expanding its oncology portfolio. For more information, visit the company's newsroom at https://ibn.fm/TNXP.
